In uremia, plasma levels of anti-protein C and anti-protein S antibodies are associated with thrombosis  by Molino, Daniela et al.
Kidney International, Vol. 68 (2005), pp. 1223–1229
In uremia, plasma levels of anti-protein C and anti-protein S
antibodies are associated with thrombosis
DANIELA MOLINO, DOMENICO DE LUCIA, ROSA MAROTTA, ALESSANDRA PERNA,
CINZIA LOMBARDI, MASSIMO CIRILLO, and NATALE GASPARE DE SANTO
First Division of Nephrology; and Department of General Pathology, Clinical Pathology and Laboratory of Hemostasis and
Thrombosis, Second University of Naples, Naples, Italy
In uremia, plasma levels of anti-protein C and anti-protein S
antibodies are associated with thrombosis.
Background. Vascular access thrombosis is an important
cause of morbidity in patients with end-stage renal failure on
maintenance hemodialysis (MHD). However, little is known
about its risk factors. The present study was undertaken to eval-
uate the role of coagulation factors, fibrinolytic factors, and anti-
phospholipid antibodies (aPL). In particular, we have evaluated
the role of anti-protein C and anti-protein S antibodies in pa-
tients on MHD with and without thrombosis because no data
are available in the literature.
Methods. The study group comprised 30 patients with throm-
botic complications (TC), 40 patients matched for age, sex, and
dialytic age with no thrombotic complications (NTC) and 400
controls. We have measured: anti-protein C antibodies, anti-
protein S antibodies, anticardiolipin antibodies (ACA), anti-
b2-glycoprotein antibodies (b2-GPI), and anti-prothrombin
antibodies (aPT), along with prothrombin time, fibrinogen,
plasminogen, protein C, protein S, anti-thrombin III, APC-
resistance test, D-dimer, tissue-type plasminogen’s activator,
plasminogen activator inhibitor-1 (PAI-1), prothrombin frag-
ment 1+2, factors of the intrinsic and extrinsic pathway, C-
reactive protein, and homocysteine.
Results. There were no significant differences between groups
for prothrombin time, fibrinogen, plasminogen, protein C, pro-
tein S, anti-thrombin III, activated protein C (APC) resistance,
D-dimer, tPA, C-reactive protein, Factors II, X, and VII. The
anti-b2-GP1 and aPT were elevated in both TC and NTC pa-
tients, compared to the control group. Significant differences
between TC and NTC groups were found for anti-protein C
and anti-protein S antibodies, ACA-IgM, PAI-1, Factor VIII,
prothrombin fragments 1+2, and homocysteine.
Conclusion. The most novel finding was a significant eleva-
tion of anti-protein C antibodies and anti-protein S antibodies in
the TC group (i.e., in patients on MHD with thrombosis of vas-
cular access). It indicates that other pathogenetic mechanisms
in addition to endothelial damage may cause hypercoagulability
in uremia.
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Patients with chronic renal failure on maintenance
hemodialysis (MHD) frequently undergo thrombotic
events that occur at the site of vascular access, as well as
in the coronary, cerebral, and retinal arteries [1–6]. The
pathogenetic mechanism is still unknown. Available data
have disclosed a state of hypofibrinolysis characterized
by elevated plasma levels of the inhibitor of tissue acti-
vator of plasminogen (PAI-1) in uremia. Data on other
coagulation factors are still being debated [7–11]. Some
studies have pointed to increased levels of Factor VII and
Factor VIII [12]; other studies have disclosed a reduction
in the concentration of activated Factor XII. Reduced
plasma concentrations of protein C (PC), anti-thrombin
III (AT III), and plasminogen have been described, but
the data need further confirmation [13].
Progress in the clinical pathology of thrombotic events
has focused on antiphospholipid (aPL) antibodies (Abs),
a heterogeneous family present in systemic lupus ery-
thematosus where thrombotic phenomena occur fre-
quently. These antibodies are also found in patients
without lupus. They have been considered to be primers
for the hypercoagulative state, although available liter-
ature does not provide a clear-cut mechanism. In fact,
aPL have been found in a variety of clinical conditions,
such as venous and arterial thrombosis, thrombocytope-
nia, cerebrovascular ischemic diseases, recurrent abor-
tion, and cutaneous lesions [14]. It is now possible to
measure lupus anticoagulant antibodies (LAC), anticar-
diolipin antibodies (ACA), antibodies to b2-glycoprotein
type I (b2-GPI), anti-prothrombin antibodies (aPT)
[15–19], anti-protein C antibodies, and anti-protein S
antibodies.
The presence of aPL might induce a prothrombotic
state by blocking protein C and protein S, potent natural
anticoagulants [15]. Plasma from patients with elevated
aPL is resistant to activated protein C and, therefore, has
a tendency to formation of thrombin. These antibodies
could bind with negatively charged target molecules rep-
resented by cofactors to Factors V and VIII, thus causing
continuously elevated levels of plasma thrombin. Current
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Table 1. Characteristics of patients with thrombotic complications
(TC) and patients with no thrombotic complications (NTC)
TC NTC P valuea
Number of patients N 30 40 0.86
M/F 15/15 22/18 0.86
Age years 54 ± 4 53 ± 5 0.37
Dialytic age months (mean) 30 ± 0.5 30 ± 0.8 1.0
Hemoglobin g/dL 11.8 ± 0.5 12.0 ± 0.5 0.10
Lipoprotein a mg/dL 16.5 ± 0.5 16 ± 0.6 0.23
Diabetes mellitus% 13.3 25.0 0.36
Hypertension% 40.0 57.5 0.22
Cigarette smoking% 40.0 47.5 0.70
Hyperlipidemia% 33.3 50.0 0.25
Percent of patients requiring 60.0 0.0 0.0001
at least 2 AVF%
History of TIA% 13.3 0.0 0.0001
Ischemic cardiopathy% 23.3 0.0 0.0001
Amputation of a limb% 16.6 0.0 0.0001
Arterial thrombotic events% 100.0 0.0 0.0001
History of aspirin use% 16.6 0.0 0.0001
aBy chi-square analysis for categorial variables (sex, diabetes, hypertension,
smoking, hyperlipidemia, need of at least 2 AVF, TIA, ischemic cardiopathy,
amputation of a limb, arterial thrombotic events, aspirin use); by ANOVA for
continuous variables (age, dialytic age, hemoglobin, and lipoprotein a).
theory holds that aPL may induce a procoagulant activity
in endothelial cells and monocytes.
Recently, aPL, specifically LAC, IgG, and IgM anticar-
diolipin antibodies (ACA-IgG and ACA-IgM), antipro-
thrombin antibodies, and anti-2-GPI antibodies, have
been extensively studied in patients on MHD [15–18].
However, the role of these antibodies in the pathogen-
esis of thrombosis is still controversial [19–22] and fur-
ther studies on their potential procoagulative role are
indicated. In summary, the data suggest that vascular en-
dothelial cell damage associated with thrombin forma-
tion is implicated in vascular occlusion in primary and
secondary aPL syndrome.
The present study explores the alternative or additional
role of a different class of antibodies, anti-protein C and
anti-protein S, on vascular endothelial cell damage asso-
ciated with hypercoagulability, in patients on MHD with
and without thrombosis of vascular access.
METHODS
Patients and controls
A total of 70 patients on MHD for 24 to 36 months
were enrolled for the study. Their characteristics are given
in Table 1. Thirty patients presented thrombotic compli-
cations of the vascular access and other vascular loca-
tions, such as coronaries, retina, and inferior limbs, and
were assigned to the TC group. Forty patients were with-
out thrombotic complications and were termed the NTC
group (Table 1).
All patients were dialyzed using an end-to-side vein-
artery anastomosis of the cephalic vein and radial artery.
Arteriovenous fistula (AVF) was monitored by Doppler
Table 2. Characteristics of vascular access at beginning of the study
Type of vascular access TC NTC
Arteriovenous fistula 100% 100%
Time to first event of thrombosis
After 3 months of dialysis 33.3% 0%
After 6 months of dialysis 13.3% 0%
After 12 months of dialysis 20% 0%
After 24 months of dialysis 33.3% 0%
Doppler analysis
Sluggish flow 0% 0%
Stenosis 0% 0%
Recirculation
Glucose test (positivity) 0% 0%
ultrasound every 6 months for dysfunction (Table 2). Pa-
tients with alterations of the primary fistula, for example,
stenosis of a portion of vascular access, were not included
in the study. Absence of recirculation was assessed every
3 months by a conventional glucose test. All patients re-
ceived conventional hemodialysis with bicarbonate bath
and used polysulfone membranes. The average length of
each dialysis was 4 hours, average blood flow was 300 to
350 mL/min, and the adequacy of dialysis was assessed
on a monthly basis using the Kt/V, which was kept in the
range 1.3 to 1.4. Heparin was used as anticoagulant in pa-
tients in all patients. Patients were studied along with 400
healthy age- and sex-matched blood donor volunteers re-
cruited at our University Hospital.
The causes of uremia in patients of the TC group were:
polycystic kidney disease (PCKD) (4 cases), chronic
pyelonephritis (14 cases), nephroangiosclerosis (4 cases),
diabetic nephropathy (5 cases), glomerulonephritis of
unknown origin (3 cases). In the NTC group causes
for uremia were: PCKD (6 cases), chronic pyelonephri-
tis (14 cases), nephroangiosclerosis (6 cases), diabetic
nephropathy (7 cases), focal and segmental glomeru-
losclerosis (3 cases), and glomerulonephritis of unknown
origin (4 cases). Hypertension, cigarette smoking, dia-
betes, and dyslipidemia are now equally distributed be-
tween groups. All patients, with the exception of those
with PCKD, received erythropoietin.
There were significant differences (P < 0.0001) be-
tween TC and NTC patients: 60% of TC patients needed
at least 2 AVF, one third had history of TIA, 23% of them
had ischemic cardiopathy, 16.6% underwent amputation
of a limb, 100% had arterial thrombotic events.
Laboratory investigations
All patients were tested for prothrombin time (PT),
activated partial thromboplastin time (APTT), fibrino-
gen (Fg), coagulation Factors of the intrinsic and extrin-
sic pathway, antithrombin III (AT-III), protein C (PC),
protein S (PS), resistance to activated protein C (APC-
resistance), prothrombin fragment 1+2 (F 1+2), plas-
minogen (PLG), tissue type plasminogen activator (tPA),
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plasminogen activator inhibitor-1 (PAI-1), homocysteine
(Hcy), C-reactive protein, anticardiolipin antibodies type
M and G (ACA-IgM and ACA-IgG), anti-prothrombin
antibodies type M and G (aPT IgM and IgG), anti-b 2
GPI, anti-protein C antibodies, and anti-protein S anti-
bodies. Genetic analysis of Factor V Leiden mutation and
prothrombin mutation were tested in all patients as very
common cardiovascular risk factors.
Blood samples (4.5 mL) were collected in silicone-
treated glass tubes by venipuncture, immediately before
the midweek hemodialysis session. Blood samples in TC
patients were collected 6 weeks after the acute ischemic
event. In this respect, the hemostatic storm was defini-
tively quenched. All patients and controls were asked
to provide base-line EDTA anticoagulated samples of
whole blood. Trisodium citrate (0.1 mol/L) in 1/10 volume
ratio was added as anticoagulant. Citrated blood was cen-
trifuged for 20 minutes at 1700g at 4◦C. The supernatant
was divided into aliquots and stored at −80◦C.
Coagulation factors were determined with a one-stage
clotting assay using commercially available reagents.
Fibrinogen concentration was determined in an au-
tomated coagulation laboratory autoanalyzer (ACL
2000; Instrumentation Laboratory, Milan, Italy). Pro-
tein C (Berichrom Protein C, Dade Behring; Marburg,
Germany) and S (Instrumentation Laboratory) plasma
levels were estimated with a functional clotting as-
say. Tissue-type plasminogen activator and PAI-1 were
assayed by enzyme immunoassay (Hyphen Biomed,
Andresy, France). Prothrombin fragment 1+2 levels
was measured by an enzyme-linked immunosorbent as-
say (ELISA) method (Enzygnost F1+2 micro; Dade
Behring).
Anticardiolipin antibodies (ACA-IgG and IgM), anti-
prothrombin antibodies (aPT-IgM and IgG), and anti-
b 2GPI (Hyphen Biomed) were measured by ELISA us-
ing commercially available kits (Hyphen Biomed).
Anti-protein C and anti-protein S were measured by
ELISA using an experimental kit (Hyphen Biomed).
Hcy concentration was determined according to Perna
et al [23]. Briefly, the procedure involves a prelim-
inary step of reduction and release from albumin,
using tri-n-butyl-phosphine in dimethylformamide, fol-
lowed by precolumn derivatization with ammonium
7-fluorobenzo-2-oxa-1, 3-diazole-4-sulphonate (SBD-F).
Separation was accomplished on a C18, 5-lm, 250 ×
4.6 mm, reverse phase column (“Luna; ” Phenomenex,
Torrance, CA, USA). The mobile phase was 0.1 mol/L
KH2PO4, pH 2.1, containing 4% acetonitrile, with a
flow rate of 1.0 mL/min. Micromolar concentrations of
homocysteine are referred to 1 liter. Detection condi-
tions were optimized for homocysteine. Fluorescence in-
tensities were measured with excitation at 385 nm and
emission at 515 nm using a Shimadzu RF-535 fluores-
cence detector (Shimadzu Co., Kyoto, Japan), equipped
Table 3. Factor II, Factor V, Factor VII, Factor X, ATIII, protein C,
protein S, plasminogen (PLG), APCr tPA, homocysteine, C-reactive
protein, PAI-1, F1+2, and Factor VIII in TC, NTC, and controls
Variables TC NTC Controls P
FII% 90 ± 5 86 ± 12 100 ± 25 n.s.
FV% 76 ± 11 81 ± 7 80 ± 20 n.s.
FVII% 96 ± 11 94 ± 10 100 ± 25 n.s.
FX% 102 ± 14 93 ± 13 100 ± 25 n.s.
ATIII% 103 ± 4 109 ± 3 98 ± 15 n.s.
Protein C% 92 ± 4 91 ± 4 98 ± 15 n.s.
Functional 80 ± 4 93 ± 6 98 ± 15 n.s.
protein S%
PLG mg/dL 87 ± 13 85 ± 4 135 ± 12 n.s.
APCr N ratio 1 ± 0.02 0.95 ± 0.01 >0.75 n.s.
tPA ng/mL 2 ± 0.7 2.3 ± 0.5 5 ± 0.5 n.s.
C-reactive protein 1.19 ± 0.19 1.02 ± 0.10 0.7 ± 0.10 P = 0.001
Homocysteine 27.8 ± 1.3 23.6 ± 2.07 7.98 ± 1.48 P = 0.001
PAI-1 ng/mL 49 ± 3.3 33 ± 3.4 22 ± 11.5 P = 0.01
F1+2 ng/mL 5.4 ± 1.3 4.5 ± 0.9 0.35 ± 0.35 P = 0.006
F VIII% 180 ± 25 122 ± 8 100 ± 2.75 P = 0.007
with a Shimadzu Chromatopac C-R6A data processor
(Shimadzu Co.).
C-reactive protein measurement was carried out ac-
cording to an immunoenzymatic method (Roche Diag-
nostics, Milan, Italy).
Genomic DNA (200 ng) from peripheral white blood
cells was extracted according to standard international
procedures. Factor V G 1691A mutation and Factor
II G20210A polymorphisms were searched using poly-
merase chain reaction (PCR) technique in a second lab-
oratory, where the investigators were unaware of each
subject’s status as a case patient or control.
Statistical analysis
Statistical evaluation was performed using the Statisti-
cal Package for Social Science (SPSS 6.1 for Macintosh,
Chicago, IL, USA). The analysis of variance (ANOVA)
test or chi-square was used to determine the significance
of differences between groups. Data were expressed as
mean values ± standard deviation (SD) and as preva-
lence. Values of P < 0.05 were considered significant.
RESULTS
No significant difference was found between TC, NTC,
and controls with respect to plasma Factor II, Factor V,
Factor VII, Factor X, protein C, protein S, ATIII, PLG,
APC-resistance and tPA (Table 3). Also, data on PT, PTT,
and fibrinogen (not included) did not disclose statisti-
cal differences between TC and NTC patients. C-reactive
protein was increased in TC and NTC patients in com-
parison with healthy controls (P = 0.001).
Hcy was increased significantly both in TC and NTC
compared to the control group (P = 0.001) (Table 3).
Patients with TC showed a significant elevation of
Factor VIII procoagulant concentration (P = 0.007), a
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Table 4. Prevalence of anti-phospholipid antibodies in patients TC
and NTC
Anti-phospholipid Normal TC NTC
antibodies values prevalence% prevalence% P valuea
anti-Protein S U/mL <10 47% 8% 0.0001
anti-Protein C U/mL <10 100% 6% 0.0001
ACA IgG U/mL <7 84% 56% 0.115
ACA IgM U/mL <5 64% 15% 0.001
aPT IgG U/mL <7 34% 37% 0.789
aPT IgM U/mL <7 14% 12% 0.055
anti-b2 GPI U/mL <5 57% 32% 0.058
Significance for P < .05.
aChi-square test.
Table 5. Absolute values of anti-phospholipid antibodies in patients
TC, NTC, and controls
Anti-phospholipid
antibodies TC NTC Control P∗
anti-Protein S U/mL 10.1 ± 2.8 6.85 ± 2.3 1.7 ± 0.5 0.0001
anti-Protein C U/mL 24.3 ± 8 7.23 ± 2.1 1.6 ± 0.5 0.0001
ACA IgG U/mL 13 ± 5.8 7.86 ± 3.6 2.63 ± 1.05 0.0001
ACA IgM U/mL 7.0 ± 3.6 3.2 ± 2.5 1.27 ± 0.29 0.001
aPT IgG U/mL 5.65 ± 2.63 6.79 ± 5.0 2.33 ± 0.88 0.04
aPT IgM U/mL 7.48 ± 2.64 4.83 ± 3.35 2.13 ± 0.77 0.04
anti-b2 GPI U/mL 5.51 ± 1.52 4.38 ± 1.1 1.7 ± 0.61 0.001
significant elevation of F1+2 plasma level (P = 0.006),
and an increased PAI-1 level (P = 0.01) compared to
NTC and the control group (Table 3). Factor VIII did not
correlate significantly with CRP.
The antiphospholipid levels are reported in Table 4 and
Table 5. Elevated anti-protein C (IgM) plasma levels are
found in 100% of TC patients and in only 6% of NTC pa-
tients (P = 0.0001), with a significant difference with the
ANOVA test (P = 0.001). Anti-protein S (IgG) plasma
levels were elevated in 47% of TC patients and in 8%
of NTC patients (P = 0.0001), with a significant differ-
ence with the ANOVA tests. Positivity for anti-b 2GPI
was found in 57% of TC patients and 32% of NTC pa-
tients (P = 0.056), with a significant difference in mean ±
SD plasma levels at ANOVA test (Table 5). The preva-
lence of ACA-IgG antibodies was 84% in TC and 56% in
NTC (P = 0.115), while the prevalence of ACA IgM anti-
bodies was 64% in TC and 15% in NTC, respectively (P =
0.001), with a significant difference for ANOVA test only
for ACA IgM plasma levels (P = 0.001). No differences
in the prevalence of aPT-IgG and aPT-IgM antibodies
were found between TC and NTC patients, while a sig-
nificant difference was found at ANOVA test considering
the different group of subjects for aPT-IgG and aPT-IgM
(P = 0.04).
Genetic analysis shows that Factor V Leiden mutation
was found in 1 TC patient and in none of the patients of
the NTC group. One patient over 70 represents 1.4% of
all patients. The prothrombin mutation was not found in
both groups. In the general population Factor V mutation
is found in about 2% of healthy subjects, while prothrom-
bin polymorphism heterozygosity is found in 4%.
DISCUSSION
Anti-protein C and anti-protein S antibodies were
measured for the first time in uremic patients on mainte-
nance hemodialysis. All available knowledge in the field
has been obtained either in patients with systemic lupus
erythematosus (SLE) or in patients without SLE but with
venous thromboembolism [24–27]. The data demonstrate
a significantly greater prevalence of anti-protein C anti-
bodies and anti-protein S antibodies in hemodialyzed pa-
tient on MHD with thrombosis of vascular access (TC),
a novel finding indicating that in uremia, in addition to
endothelial damage [28, 29], other pathogenetic mecha-
nisms may cause hypercoagulability.
In order to understand the importance of present re-
sults, it might be instrumental to assign a proper role to
each of the factors studied by including them in a possi-
ble model of hemostatic derangement in uremia. PAI-1
is a molecule of endothelial origin and is overproduced
in endothelial dysfunctions, such as in uremia. Patients
with thrombotic complications show a significant increase
in PAI-1, FVIII, F1+2 compared to controls, as well as
to patients without thrombotic complications. The ex-
cess PAI-1 released in the bloodstream inhibits tPA and
blocks the fibrinolysis system, causing hypofibrinolysis
(i.e., low efficiency thrombolysis). Despite hypofibrinol-
ysis, an increase of D-dimers was observed, but it should
be stressed that their increase is lower than expected,
considering that the coagulation pathway is activated in
excess (Fig. 1).
F1+2, an indicator of abnormal activation of the co-
agulation pathway, is a molecule released during the
activation of prothrombin to thrombin. Increased lev-
els of F1+2 could be related to the presence of anti-
prothrombin antibodies (Abs) and anti-b2 GP-I Abs. In
fact, anti-prothrombin blocks the prothrombinase com-
plex in a status of activation. This mechanism continu-
ously stimulates the transformation of prothrombin to
thrombin and the consequent release of F1+2 (Fig. 1).
In turn, anti-b2 GP-I antibodies compete with Factor V
in binding b2 GP-I. Therefore, when b2 GP-I is bound
to the antibody, it is no longer available to bind Factor V
and present it to the protein C system, which is the path-
way that inactivates activated Factor V [30]. Factor V (not
inactivated) forms the prothrombinase complex and in-
creases the formation of thrombin and F1+2 (Fig. 1).
Increased Factor VIII causes activation of the coag-
ulation pathway because Factor VIII (Fig. 1) is an im-
portant cofactor in the activation of Factor X by the
tenase complex. Elevated Factor VIII could be poten-
tially prothrombotic either by increasing the stability of
the tenase complex or by conferring a relative resistance
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Secondary hemostasis
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FXIIaFXII
Endothelial cells
TM
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Fig. 1. Synopsis of all intrinsic and extrinsic
pathways of secondary hemostasis that lead
to thrombin formation and fibrin deposition.
White squares and circles indicate derange-
ments in patients on maintenance hemodialy-
sis. Broken lines indicate inhibition.
to APC degradation. Elevated levels of Factor VIII were
associated with venous thrombosis in the Leiden Throm-
bophilia Study, and the association has also been ob-
served subsequently [31].
It is well known that an increase in Factor VIII is due
to endothelial damage as well to the presence of the anti-
protein C antibodies. Elevations of Factor VIII in the
present study were not associated with the inflammatory
state (PCR vs. FVIII, R = 0.112, P = 0.742).
Hcy levels produce interactions with the anticoagulant
pathway, as well as with the fibrinolytic system and the
endothelial functions. These interactions lead to inhibi-
tion of thrombomodulin-dependent activated protein C
system, which, in turn, leads to persistent thrombin ac-
tivation and formation. The activated protein C system
also interferes with tPA endothelial release into the vas-
culature, thus predisposing to hypofibrinolysis. Finally,
high Hcy plasma levels may interfere with subendothelial
cell proliferation via metalloproteinase inducible gene
activation such as MPP-9 subtype. Biologically plausi-
ble mechanisms of vascular damage have been suggested,
including effects on endothelium, platelet functions, co-
agulation factors, and lipoprotein oxidation. Interactions
between Hcy plasma levels and conventional risk factors
may have implications for risk management and for our
understanding of the causes of vascular access thrombosis
[32, 33].
In order to understand the possible role for anti-protein
C and anti-protein S antibodies in the hemostatic de-
rangement in uremia, one should start from the fact that
anti-protein C antibodies induce hypercoagulability by
inhibiting the protein C system, and by blocking the enzy-
matic inactivation of Factor VIII, resulting in an increase
of activated Factor VIII. This, in turn, stimulates the for-
mation of thrombin, which, after saturating all the throm-
bomodulin binding sites, is diverted to the formation of
fibrin. The thrombin excess increases the procoagulation
pathway rather than showing the anticoagulation effect
of binding with thrombomodulin.
Activated protein C acts as an anticoagulant by
cleaving multiple bonds and thereby destroying the
membrane-bound activated forms of coagulation Fac-
tors V (Va) and VIII (VIIIa). This reaction is accel-
erated by protein S acting as a cofactor. Like protein
C, protein S is a glycoprotein that undergoes vitamin
K–dependent post-translational carboxylations to form
gamma-carboxyglutamic acid (“Gla”) residues that allow
its binding to negatively charged phospholipid surfaces.
Protein S acts as a cofactor by increasing the affinity of
activated protein C for phospholipids in the formation of
the membrane-bound protein C-ase complex.
Anti-protein S antibodies target protein S, which is
cofactor of protein Cact. We can hypothesize that anti-
protein S antibodies induce hypercoagulability by inhibit-
ing the protein C system and by blocking the enzymatic
inactivation of Factor VIII, resulting in an increase of ac-
tivated Factor VIII (Fig. 1).
The present data do not assign a role to Factor V and
prothrombin mutations; however, further investigation is
warranted to define the role of genetic analysis in vascular
access thrombosis.
For the sake of comparison, the above data are pre-
sented in Table 6 along with data from some very relevant
papers in the field. In the table, one can appreciate the
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C role of our data and the time course of advancement in
the field. It is evident that previous studies on coagulation
in uremia have mainly focused their attention on differ-
ences in coagulation cascade, and/or on anticardiolipin
antibodies and lupus anticoagulant, without screening for
different subclasses of autoantibodies against phospho-
lipid, endothelial, or platelet antigens.
CONCLUSION
We conclude that thrombotic complications in ure-
mic patients are the result of changes in the secondary
hemostasis and in fibrinolysis, differentiating them from
hemorrhagic complications due to changes in primary
hemostasis. The alterations of secondary hemostasis and
fibrinolysis are due to endothelial damage and to the ad-
ditive effects of some classes of antiphospholipid antibod-
ies. These changes, for unknown reasons, are more severe
in some patients, who are consequently more prone to
thrombotic complications. Studies on the antigens of vas-
cular endothelium to which autoantibodies bind might
provide a further insight into their pathogenicity for
thrombosis in patients on MHD.
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